Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis

Inclusion Criteria: * Living in the study area for a continuous period of 3 years * Adult aged 18 years and above * Are willing and able to consent to this study * Meet the definitions of active symptomatic NCC * Have late onset of epilepsy or history of seizures, epileptic seizures * Subjects willing to undergo diagnostic procedures * Subjects medically stable enough for trial medication to be initiated * Subjects willing to be hospitalized for 11-20 days to receive treatment for NCC * Subjects willing to be followed up for one year following receipt of study medication Exclusion Criteria: * Women pregnant or breastfeeding * Symptomatic NCC with cysts in extra-parenchymal location (sub-arachnoid and/or ventricles) * Have uncontrolled hypertension and/or diabetes * Have chronic consuming illness such as cancer or mental handicap to not allow them to follow the study instructions * Have severe immunodeficiency eg. HIV/AIDS or Autoimmune diseases * Already known allergies to albendazole or praziquantel * Subject taking part in another clinical/pharmacological study in the 30 days preceding enrollment